Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer

Molecular and Cellular Endocrinology

Volumn 186, Issue 1, 2002, Pages 69-79

  Yang, Eddy S ^a   Maiorino, Carol A ^a   Roos, Bernard A ^a,b   Knight, Selena R ^a   Burnstein, Kerry L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen independence; Androgen receptor; Cyclin dependent kinase inhibitor; p21WAF1 CIP1; p27KIP1; Vitamin D receptor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; COLECALCIFEROL; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0037081874     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00671-2     Document Type: Article

References (41)

1. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer
2. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential
3. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
4. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
5. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf, p27kip1, and E-cadherin
6. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy
7. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
8. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells
9. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate
10. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression
11. Differential recognition of target genes by nuclear receptor monomers, dimmers, and heterodimers
12. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade
13. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
14. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
15. kip1 in androgen-induced cell cycle arrest
16. New functional activities for the p21 family of CDK inhibitors
17. Human primary prostate tumor cell line, ALVA31: a new model for studying the hormonal regulation of prostate tumor cell growth
18. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells
19. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D3
20. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines
21. Activation of the human androgen receptor through a protein kinase: a signaling pathway
22. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression
23. Vitamin D: a modulator of cell proliferation and differentiation
24. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase: a signal transduction pathways
25. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells
26. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs
27. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase
28. CDK inhibitors: positive and negative regulators of G1-phase progression
29. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
30. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma
31. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride
32. Newly identified actions of the vitamin D endocrine system
33. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
34. 1α,25-Dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent
35. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCA 2A
36. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms
37. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
38. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
39. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation